Biomarker-based drug safety assessment in the age of systems pharmacology: From foundational to regulatory science

Biomarkers in Medicine

Volumn 9, Issue 11, 2015, Pages 1241-1252

  Zhang, Chen ^a   Hong, Huixiao ^b   Mendrick, Donna L ^b   Tang, Yun ^a   Cheng, Feixiong ^a,c  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^c SICHUAN UNIVERSITY   (China)

Author keywords

biomarker; drug safety assessment; regulatory science; systems biology; systems pharmacology

Indexed keywords

BIOLOGICAL MARKER; DRUG; PHARMACOLOGICAL BIOMARKER;

AGE; AMINO ACID SEQUENCE; BIOINFORMATICS; CATALYSIS; DRUG RESEARCH; DRUG SAFETY; GENETIC ASSOCIATION; LIGAND BINDING; MOLECULAR DOCKING; NEXT GENERATION SEQUENCING; PHARMACODYNAMICS; PHARMACOLOGICAL SCIENCE; PHENOTYPE; PROTEIN INTERACTION; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SYSTEMS PHARMACOLOGY; ANIMAL; HUMAN; METABOLISM; PHARMACOLOGY; PROCEDURES; SAFETY; SOCIAL CONTROL; SYSTEMS BIOLOGY;

ANIMALS; BIOMARKERS, PHARMACOLOGICAL; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY; SAFETY; SOCIAL CONTROL, FORMAL; SYSTEMS BIOLOGY;

EID: 84947765114     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.15.81     Document Type: Review

References (99)

1. Cheng F, Li W, Liu G, Tang Y. In silico ADMET prediction: recent advances, current challenges and future trends. Curr. Top. Med. Chem. 13(11), 1273-1289 (2013).
2. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4(11), 682-690 (2008).
3. Cheng F, Li W, Wu Z et al. Prediction of polypharmacological profiles of drugs by the integration of chemical, side effect, and therapeutic space. J. Chem. Inf. Model. 53(4), 753-762 (2013).
4. Schenone M, Dancik V, Wagner BK, Clemons PA. Target identification and mechanism of action in chemical biology and drug discovery. Nat. Chem. Biol. 9(4), 232-240 (2013).
5. Besnard J, Ruda GF, Setola V et al. Automated design of ligands to polypharmacological profiles. Nature 492(7428), 215-220 (2012).
6. Wang D, Wang M, Cheng Y, Fitzgerald GA. Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Curr. Opin. Pharmacol. 5(2), 204-210 (2005).
7. Antunes AM, Godinho AL, Martins IL et al. Protein adducts as prospective biomarkers of nevirapine toxicity. Chem. Res. Toxicol. 23(11), 1714-1725 (2010).
8. Lounkine E, Keiser MJ, Whitebread S et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature 486(7403), 361-367 (2012).
9. Hong H, Goodsaid F, Shi L, Tong W. Molecular biomarkers: a US FDA effort. Biomark Med. 4(2), 215-225 (2010).
10. Science, Medicine, and Animals. http://www. nap. edu/catalog/10733. html
11. Li AP. A comprehensive approach for drug safety assessment. Chem. Biol. Interact. 150(1), 27-33 (2004).
12. Collins FS, Gray GM, Bucher JR. Toxicology. Transforming environmental health protection. Science 319(5865), 906-907 (2008).
13. Cheng F, Yu Y, Shen J et al. Classification of cytochrome P450 inhibitors and noninhibitors using combined classifiers. J. Chem. Inf. Model. 51(5), 996-1011 (2011).
14. Cheng F, Yu Y, Zhou Y et al. Insights into molecular basis of cytochrome p450 inhibitory promiscuity of compounds. J. Chem. Inf. Model. 51(10), 2482-2495 (2011).
15. Cheng F, Shen J, Yu Y et al. In silico prediction of Tetrahymena pyriformis toxicity for diverse industrial chemicals with substructure pattern recognition and machine learning methods. Chemosphere 82(11), 1636-1643 (2011).
16. Cheng F, Li W, Zhou Y et al. admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J. Chem. Inf. Model. 52(11), 3099-3105 (2012).
17. Chen Y, Cheng F, Sun L et al. Computational models to predict endocrine-disrupting chemical binding with androgen or oestrogen receptors. Ecotoxicol. Environ. Saf. 110, 280-287 (2014).
18. Li X, Chen L, Cheng F et al. In silico prediction of chemical acute oral toxicity using multi-classification methods. J. Chem. Inf. Model. 54(4), 1061-1069 (2014).
19. Xu C, Cheng F, Chen L et al. In silico prediction of chemical Ames mutagenicity. J. Chem. Inf. Model. 52(11), 2840-2847 (2012).
20. Hong H, Branham WS, Dial SL et al. Rat alpha-Fetoprotein binding affinities of a large set of structurally diverse chemicals elucidated the relationships between structures and binding affinities. Chem. Res. Toxicol. 25(11), 2553-2566 (2012).
21. Ng HW, Zhang W, Shu M et al. Competitive molecular docking approach for predicting estrogen receptor subtype alpha agonists and antagonists. BMC Bioinformatics 15(Suppl. 11), S4 (2014).
22. Sturla SJ, Boobis AR, Fitzgerald RE et al. Systems toxicology: from basic research to risk assessment. Chem. Res. Toxicol. 27(3), 314-329 (2014).
23. Bai JP, Abernethy DR. Systems pharmacology to predict drug toxicity: integration across levels of biological organization. Annu. Rev. Pharmacol. Toxicol. 53, 451-473 (2013).
24. Meyer UA, Zanger UM, Schwab M. Omics and drug response. Annu. Rev. Pharmacool. Toxicol. 53, 475-502 (2013).
25. Zhao S, Iyengar R. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu. Rev. Pharmacool. Toxicol. 52, 505-521 (2012).
26. Zhang C, Cheng F, Sun L et al. In silico prediction of chemical toxicity on avian species using chemical category approaches. Chemosphere 122, 280-287 (2015).
27. Shen J, Cheng F, Xu Y, Li W, Tang Y. Estimation of ADME properties with substructure pattern recognition. J. Chem. Inf. Model. 50(6), 1034-1041 (2010).
28. Johnson CH, Patterson AD, Idle JR, Gonzalez FJ. Xenobiotic metabolomics: major impact on the metabolome. Annu. Rev. Pharmacool. Toxicol. 52, 37-56 (2012).
29. Audouze K, Grandjean P. Application of computational systems biology to explore environmental toxicity hazards. Environ. Health Perspect. 119(12), 1754-1759 (2011).
30. Hoeng J, Talikka M, Martin F et al. Case study: the role of mechanistic network models in systems toxicology. Drug Discov. Today 19(2), 183-192 (2014).
31. Kuhn M, Al Banchaabouchi M, Campillos M et al. Systematic identification of proteins that elicit drug side effects. Mol. Syst. Biol. 9, 663 (2013).
32. Cheng F, Li W, Zhou Y et al. Prediction of human genes and diseases targeted by xenobiotics using predictive toxicogenomic-derived models (PTDMs). Mol. BioSyst. 9(6), 1316-1325 (2013).
33. Cheng F, Zhou Y, Li J et al. Prediction of chemical-protein interactions: multitarget-QSAR versus computational chemogenomic methods. Mol. BioSyst. 8(9), 2373-2384 (2012).
34. Cheng F, Zhou Y, Li W, Liu G, Tang Y. Prediction of chemical-protein interactions network with weighted network-based inference method. PLoS ONE 7(7), e41064 (2012).
35. Li J, Wu Z, Cheng F et al. Computational prediction of microRNA networks incorporating environmental toxicity and disease etiology. Sci. Rep. 4, 5576 (2014).
36. Hong H, Tong W. Emerging efforts for discovering new biomarkers of liver disease and hepatotoxicity. Biomark Med. 8(2), 143-146 (2014).
37. Wang Y, Chen T, Tong W. miRNAs and their application in drug-induced liver injury. Biomark Med. 8(2), 161-172 (2014).
38. Cheng F, Li W, Wang X et al. Adverse drug events: database construction and In silico prediction. J. Chem. Inf. Model. 53(4), 744-752 (2013).
39. Lu W, Cheng F, Jiang J et al. FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach. Sci. Rep. 5, 8114 (2015).
40. Cheng F, Liu C, Jiang J et al. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput. Biol. 8(5), e1002503 (2012).
41. Olson S, Robinson S, Giffin R. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. ISBN: 978-0-309-13124-7. The National Academies Press, Washington, DC, USA (2009). http://wwwnapedu/catalog/12587
42. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001).
43. Knox C, Law V, Jewison T et al. DrugBank 3. 0: a comprehensive resource for "omics" research on drugs. Nucleic Acids Res. 39(Database issue), D1035-D1041 (2011).
44. Zhu F, Shi Z, Qin C et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 40(Database issue), D1128-D1136 (2012).
45. Gaulton A, Bellis LJ, Bento AP et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40(Database issue), D1100-D1107 (2012).
46. Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 35(Database issue), D198-D201 (2007).
47. Hewett M, Oliver DE, Rubin DL et al. PharmGKB: the pharmacogenetics knowledge base. Nucleic Acids Res. 30(1), 163-165 (2002).
48. Kuhn M, von Mering C, Campillos M, Jensen LJ, Bork P. STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res. 36(Database issue), D684-D688 (2008).
49. Wang Y, Xiao J, Suzek TO et al. PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res. 37(Web Server issue), W623-W633 (2009).
50. Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P. A side effect resource to capture phenotypic effects of drugs. Mol. Syst. Biol. 6, 343 (2010).
51. Tatonetti NP, Ye PP, Daneshjou R, Altman RB. Data-driven prediction of drug effects and interactions. Sci. Transl. Med. 4(125), 125ra131 (2012).
52. Davis AP, Murphy CG, Saraceni-Richards CA et al. Comparative toxicogenomics database: a knowledgebase and discovery tool for chemical-gene-disease networks. Nucleic Acids Res. 37(Database issue), D786-D792 (2009).
53. Dix DJ, Houck KA, Martin MT et al. The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol. Sci. 95(1), 5-12 (2007).
54. National Toxicology Program. DrugMatrix®. https://ntp. niehs. nih. gov/drugmatrix/index. html
55. diXa. www. dixa-fp7. eu
56. Hendrickx DM, Boyles RR, Kleinjans JC, Dearry A. Workshop report: Identifying opportunities for global integration of toxicogenomics databases, 26-27 June 2013, Research Triangle Park, NC, USA. Arch. Toxicol. 88(12), 2323-2332 (2014).
57. Chatr-Aryamontri A, Breitkreutz BJ, Heinicke S et al. The BioGRID interaction database: 2013 update. Nucleic Acids Res. 41(Database issue), D816-D823 (2013).
58. Franceschini A, Szklarczyk D, Frankild S et al. STRING v9. 1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 41(Database issue), D808-D815 (2013).
59. Kanehisa M, Goto S, Sato Y et al. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 42(Database issue), D199-D205 (2014).
60. Kelder T, van Iersel MP, Hanspers K et al. WikiPathways: building research communities on biological pathways. Nucleic Acids Res. 40(Database issue), D1301-D1307 (2012).
61. Cerami EG, Gross BE, Demir E et al. Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res. 39(Database issue), D685-D690 (2011).
62. Kim Kjaerulff S, Wich L, Kringelum J et al. ChemProt-2. 0: visual navigation in a disease chemical biology database. Nucleic Acids Res. 41(Database issue), D464-D469 (2013).
63. Wishart D, Arndt D, Pon A et al. T3DB: the toxic exposome database. Nucleic Acids Res. 43(Database issue), D928-D934 (2015).
64. Croft D, Mundo AF, Haw R et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 42(Database issue), D472-D477 (2014).
65. Keshava Prasad TS, Goel R, Kandasamy K et al. Human protein reference database 2009 update. Nucleic Acids Res. 37(Database issue), D767-D772 (2009).
66. Kerrien S, Aranda B, Breuza L et al. The IntAct molecular interaction database in 2012. Nucleic Acids Res. 40(Database issue), D841-D846 (2012).
67. Juan-Blanco T, Duran-Frigola M, Aloy P. IntSide: a web server for the chemical and biological examination of drug side effects. Bioinformatics 31(4), 612-613 (2015).
68. Doerks T, Copley RR, Schultz J, Ponting CP, Bork P. Systematic identification of novel protein domain families associated with nuclear functions. Genome Res. 12(1), 47-56 (2002).
69. Batagelj V, Mrvar A. Pajek-program for large network analysis. Connections 21(2), 47-57 (1998).
70. Duran-Frigola M, Rossell D, Aloy P. A chemo-centric view of human health and disease. Nat. Commun. 5, 5676 (2014).
71. Xu Z, Cheng F, Da C, Liu G, Tang Y. Pharmacophore modeling of human adenosine receptor A((2)A) antagonists. J. Mol. Model. 16(12), 1867-1876 (2010).
72. Ma'ayan A, Rouillard AD, Clark NR et al. Lean Big Data integration in systems biology and systems pharmacology. Trends Pharmacol. Sci. 35(9), 450-460 (2014).
73. Shannon P, Markiel A, Ozier O et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13(11), 2498-2504 (2003).
74. Hur J, Zhao C, Bai JP. Systems pharmacological analysis of drugs inducing Stevens-Johnson syndrome and toxic epidermal necrolysis. Chem. Res. Toxicol. 28(5), 927-934 (2015).
75. Harrison C. GlaxoSmithKline opens the door on clinical data sharing. Nat. Rev. Drug Discov. 11(12), 891-892 (2012).
76. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science 321(5886), 263-266 (2008).
77. Berman HM, Westbrook J, Feng Z et al. The Protein Data Bank. Nucleic Acids Res. 28(1), 235-242 (2000).
78. Duran-Frigola M, Mosca R, Aloy P. Structural systems pharmacology: the role of 3D structures in nextgeneration drug development. Chem. Biol. 20(5), 674-684 (2013).
79. Xie L, Li J, Bourne PE. Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput. Biol. 5(5), e1000387 (2009).
80. Yang L, Chen J, He L. Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome. PLoS Comput. Biol. 5(7), e1000441 (2009).
81. Yang L, Wang KJ, Chen JA et al. Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome-clozapine-induced agranulocytosis as a case study. PLoS Comput. Biol. 7(3), e1002016 (2011).
82. Berger SI, Iyengar R. Role of systems pharmacology in understanding drug adverse events. Wires Rev. Syst. Biol. Med. 3(2), 129-135 (2011).
83. Jacunski A, Tatonetti NP. Connecting the dots: applications of network medicine in pharmacology and disease. Clin. Pharmacol. Ther. 94(6), 659-669 (2013).
84. Tujios S, Fontana RJ. Mechanisms of drug-induced liver injury: from bedside to bench. Nat. Rev. Gastroenterol. Hepatol. 8(4), 202-211 (2011).
85. Lee WM. Drug-induced hepatotoxicity. N. Engl. J. Med. 349(5), 474-485 (2003).
86. Wang X, Thijssen B, Yu H. Target essentiality and centrality characterize drug side effects. PLoS Comput. Biol. 9(7), e1003119 (2013).
87. Chen X, Liu X, Jia X et al. Network characteristic analysis of ADR-related proteins and identification of ADR-ADR associations. Sci. Rep. 3, 1744 (2013).
88. FitzGerald GA. Regulatory science: what it is and why we need it. Clin. Pharmacol. Ther. 89(2), 291-294 (2011).
89. Zineh I, Woodcock J. Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluation. Clin. Pharmacol. Ther. 93(6), 515-525 (2013).
90. Califf RM, Ostroff S. FDA as a catalyst for translation. Sci. Transl. Med. 7(296), 296ed299 (2015).
91. Maliepaard M, Nofziger C, Papaluca M et al. Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nat. Rev. Drug Discov. 12(2), 103-115 (2013).
92. Pacanowski MA, Leptak C, Zineh I. Next-generation medicines: past regulatory experience and considerations for the future. Clin. Pharmacol. Ther. 95(3), 247-249 (2014).
93. Daly AK. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annu. Rev. Pharmacool. Toxicol. 52, 21-35 (2012).
94. Alsbeih G, El-Sebaie M, Al-Harbi N et al. SNPs in genes implicated in radiation response are associated with radiotoxicity and evoke roles as predictive and prognostic biomarkers. Radiat. Oncol. 8, 125 (2013).
95. Fachal L, Gomez-Caamano A, Barnett GC et al. A threestage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24. 1. Nat. Genet. 46(8), 891-894 (2014).
96. Nan H, Hutter CM, Lin Y et al. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA 313(11), 1133-1142 (2015).
97. Hammad TA, Neyarapally GA, Iyasu S, Staffa JA, Dal Pan G. The future of population-based postmarket drug risk assessment: a regulator's perspective. Clin. Pharmacol. Ther. 94(3), 349-358 (2013).
98. Mandl KD, Kohane IS. Federalist principles for healthcare data networks. Nat. Biotechnol. 33(4), 360-363 (2015).
99. Blumenthal D. Launching HITECH. N. Engl. J. Med. 362(5), 382-385 (2010).